MedTrace Logo

Comparing Doses of Intrathecal Dexmedetomidine

NCT07395271 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-02-09

No results posted yet for this study

Summary

To compare the duration of sensory and motor blockade produced by two different intrathecal doses of dexmedetomidine (5 µg and 10 µg) when added to hyperbaric bupivacaine in patients undergoing elective cesarean section

Conditions

  • Dexmedetomidine

Interventions

DRUG

Dexmedetomidine 5 mcg

12.5 mg (2.5 mL) of 0.5% hyperbaric bupivacaine + 5 µg dexmedetomidine

DRUG

Dexmedetomidine 10 mcg

12.5 mg (2.5 mL) of 0.5% hyperbaric bupivacaine + 10 µg dexmedetomidine

Sponsors & Collaborators

  • Bahria International Hospital

    lead UNKNOWN

Principal Investigators

  • azher munir, mbbs · Bahria International Hospital

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-22
Primary Completion
2026-01-21
Completion
2026-01-21

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07395271 on ClinicalTrials.gov